Skip to main content
. Author manuscript; available in PMC: 2016 Apr 10.
Published in final edited form as: Cancer Lett. 2015 Jan 28;359(2):299–306. doi: 10.1016/j.canlet.2015.01.037

Fig. 2.

Fig. 2

(A) Negative correlations between sst2/sst5TMD4 ratio and GH and IGF1 levels after 3 and 6 months postsurgical treatment with octreotide-LAR in acromegalic patients. (B) sst2/sst5TMD4 ratio in pharmacologically controlled and uncontrolled patients with GH secreting adenomas (GHomas). (C) sst5TMD4 expression and sst2/sst5TMD4 ratio in patients with GNAS negative and positive tumors.